Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bob T. Li, MD"'
Autor:
Malinda Itchins, BMedSci, M.B.B.S., FRACP, PhD, Shirley Liang, BSc, Chris Brown, MBiostats, BSc, Tristan Barnes, BSc (Med), M.B.B.S., FRACP, Gavin Marx, BSc, M.B.B.S., FRACP, Venessa Chin, M.B.B.S., FRACP, PhD, Steven Kao, BHB, MBChB, PhD, FRACP, Po Yee Yip, MBChB, FRACP, PhD, Antony J. Mersiades, BMedSc, M.B.B.S., FRACP, MMed (Clin. Epi), Adnan Nagrial, M.B.B.S., FRACP, PhD, Victoria Bray, M.B.B.S., FRACP, PhD, Geoffrey Peters, BPharm, M.B.B.S., FRACP, Sagun Parakh, BSc, MBChB, FRACP, PhD, Kavita Garg, PhD, Bob T. Li, MD, PhD, MPH, Matthew McKay, PhD, Kenneth O'Byrne, M.B.B.S., FRACP, FRCPA, MD, Thomas John, M.B.B.S., FRACP, PhD, Anthony J. Gill, MD, FRCPA, Mark P. Molloy, PhD, Benjamin J. Solomon, M.B.B.S., FRACP, PhD, Nick Pavlakis, BSc, M.B.B.S., MMed (Clin. Epi), PhD, FRACP
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100703- (2024)
Introduction: ALK-positive lung cancers represent a molecularly diverse disease. With drug exposure, driving selection pressure, and resistance pathways, disease relapse will emerge. There is compelling rationale to investigate novel treatment strate
Externí odkaz:
https://doaj.org/article/c4d94b5682fa4f42ad7cf98e2bbfcd9a
Autor:
Brandon S. Imber, MD, MA, Ryka Sehgal, MD, Rachel Saganty, MD, Anne S. Reiner, MPH, A. Turan Ilica, MD, Emily Miao, PharmD, Bob T. Li, MD, Gregory J. Riely, MD, Helena A. Yu, MD, Katherine S. Panageas, DrPH, Robert J. Young, MD, Luke R.G. Pike, MD, DPhil, Nelson S. Moss, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100607- (2023)
Introduction: Patients with EGFR-mutant NSCLC have a high incidence of brain metastases. The EGFR-directed tyrosine kinase inhibitor osimertinib has intracranial activity, making the role of local central nervous system (CNS)-directed therapies, such
Externí odkaz:
https://doaj.org/article/eb50687c81bc4fa09768c4beb4a3d785
Autor:
Benjamin H. Lok, MD, Jennifer Ma, BA, Amanda Foster, BS, Carmen A. Perez, MD, PhD, Weiji Shi, MS, Zhigang Zhang, PhD, Bob T. Li, MD, MPH, Charles M. Rudin, MD, PhD, Andreas Rimner, MD, Abraham J. Wu, MD
Publikováno v:
Advances in Radiation Oncology, Vol 2, Iss 4, Pp 548-554 (2017)
Purpose: Brain metastases are common in patients with limited-stage small cell lung cancer (LS-SCLC) due to the inability of most chemotherapeutics to penetrate the blood–brain barrier. Prophylactic cranial irradiation (PCI) is therefore recommende
Externí odkaz:
https://doaj.org/article/3530cd3aab2a425a8cac266dc41ec74c